Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin‐American cohort of 212 patients
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25987
Abstract: AUTHOR CONTRIBUTIONS Contribution: K.B.B.P., principal investigator of this trial, conceived and designed the study; E.V.D.P., M.T.D. and G.O.D. were sub-investigators. KBBP and EVDP contributed to the data interpretation and drafted the manuscript. K.B.B.P., E.V.D.P., A.B.P.L.,… read more here.
Keywords: thrombocytopenia predictor; predictor survival; severe thrombocytopenia; survival response ... See more keywords
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26524
Abstract: plasma cells: first, antibody-mediated cellular cytotoxicity (complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, antibody-dependent cellular cytotoxicity), second, killing of immunosuppressive populations of T-regulatory and B-regulatory lymphocytes, and myeloid-derived suppressor cells that express CD38 and lastly immunomodulation mediated… read more here.
Keywords: agents venetoclax; poems syndrome; hypomethylating agents; allogeneic transplantation ... See more keywords
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30532
Abstract: Myelodysplastic syndromes (MDS) are genetically, biologically, and clinically very heterogeneous. Although allogeneic stem cell transplantation (alloSCT) remains the only intervention with a potential for cure, less than 5% of patients undergo transplantation because of age… read more here.
Keywords: myelodysplastic syndromes; histone deacetylase; higher risk; hypomethylating agents ... See more keywords
The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.28091
Abstract: Induction of reactive oxygen species (ROS), an important process for the cytotoxicity of various acute myeloid leukemia (AML) therapies including hypomethylating agents (HMAs), concurrently activates the NF‐E2‐related factor 2 (Nrf2) antioxidant response pathway which in… read more here.
Keywords: venetoclax; nrf2 antioxidant; treatment; hypomethylating agents ... See more keywords
Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03719-6
Abstract: Patients with acute myeloid leukemia (AML) who progress after exposure to hypomethylating agents (HMA) have a dismal prognosis. We hypothesized that the addition of venetoclax, a BCL-2 inhibitor, to AML patients who previously failed HMA… read more here.
Keywords: patients acute; myeloid leukemia; venetoclax patients; hypomethylating agents ... See more keywords
Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.03.001
Abstract: PURPOSE Myelodysplastic syndromes (MDS) are characterized by variable degrees of clinical outcomes. Until now, hypomethylating agents (HMAs) are the only drugs that have been approved by FDA in remedying this complicated prognosis disease, but without… read more here.
Keywords: myelodysplastic syndromes; analysis; efficacy; hypomethylating agents ... See more keywords
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia research"
DOI: 10.1016/j.leukres.2021.106773
Abstract: BACKGROUND Older patients encompass about 75 % of patients with acute myeloid leukemia (AML). Today therapeutic options to prevent relapse in older patients who managed to achieve complete remission (CR) after intensive chemotherapy are scarce.… read more here.
Keywords: hypomethylating agents; maintenance therapy; maintenance; meta analysis ... See more keywords
Wilm’s Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01039-2
Abstract: Hypomethylating agents (HMA) for relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic transplantation (allo-SCT) are most effective when used at the stage of molecular relapse. As Wilm’s Tumor 1 (WT1)- expression has… read more here.
Keywords: allogeneic transplantation; molecular relapse; relapse; mds allogeneic ... See more keywords
Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Medicine"
DOI: 10.1080/07853890.2022.2164611
Abstract: Abstract Background There is a lack of evidence regarding whether combination therapy of hypomethylating agents (HMAs) has better outcomes than HMA monotherapy in patients with Philadelphia chromosome-negative accelerated or blast phase myeloproliferative neoplasms (MPN-AP/BP). Materials… read more here.
Keywords: hypomethylating agents; combination; hmas plus; accelerated blast ... See more keywords
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000000685
Abstract: Abstract Epigenetic regulation includes changes of DNA methylation and modifications of histone proteins and is essential for normal physiologic functions, especially for controlling gene expression. Epigenetic dysregulation plays a key role in disease pathogenesis and… read more here.
Keywords: histone deacetylase; deacetylase inhibitors; hypomethylating agents; epigenetic therapies ... See more keywords
Treatment in patients with acute myeloid leukemia/high-risk myelodysplastic syndrome with hypomethylating agents: Day-hospital management compared to home care setting.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of haematology"
DOI: 10.1111/ejh.14012
Abstract: OBJECTIVES Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents (HMAs) +/- venetoclax of frail… read more here.
Keywords: leukemia high; high risk; hypomethylating agents; care ... See more keywords